1
|
Wang Y, Troutman MC, Hofmann C, Gonzalez A, Song L, Levin R, Pixley HY, Kearns K, DePhillips P, Loughney JW. Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development. Front Immunol 2024; 15:1356600. [PMID: 38410513 PMCID: PMC10895029 DOI: 10.3389/fimmu.2024.1356600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 01/29/2024] [Indexed: 02/28/2024] Open
Abstract
Dengue fever has remained a continuing global medical threat that impacts half of the world's population. Developing a highly effective dengue vaccine, with live-attenuated tetravalent vaccines as leading candidates, remains essential in preventing this disease. For the development of live virus vaccines (LVVs), potency measurements play a vital role in quantifying the active components of vaccine drug substance as well as drug product during various stages of research, development, and post-licensure evaluations. Traditional plaque-based assays are one of the most common potency test methods, but they generally take up to weeks to complete. Less labor and time-intensive potency assays are thus called for to aid in the acceleration of vaccine development, especially for multivalent LVVs. Here, we introduce a fully automated, 96-well format µPlaque assay that has been optimized as a high-throughput tool to evaluate process and formulation development of a live-attenuated tetravalent dengue vaccine. To the best of our knowledge, this is the first report of a miniaturized viral plaque method for dengue with full automation via an integrated robotic system. Compared to the traditional manual plaque assay, this newly developed method substantially reduces testing time by approximately half and allows for the evaluation of over ten times more samples per run. The fully automated workflow, from cell culture to plaque counting, significantly minimizes analyst hands-on time and improves assay repeatability. The study presents a pioneering solution for the rapid measurement of LVV viral titers, offering promising prospects for advancing vaccine development through high-throughput analytics.
Collapse
Affiliation(s)
- Yi Wang
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Matthew C. Troutman
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Carl Hofmann
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Ariel Gonzalez
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Liping Song
- Biostatistics, Merck & Co., Inc., Rahway, NJ, United States
| | - Robert Levin
- Vaccine Drug Product Development, Merck & Co., Inc, Rahway, NJ, United States
| | - Heidi Yoder Pixley
- Vaccine Drug Product Development, Merck & Co., Inc, Rahway, NJ, United States
| | - Kristine Kearns
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - Pete DePhillips
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| | - John W. Loughney
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ, United States
| |
Collapse
|
2
|
Ooi EE, Kalimuddin S. Insights into dengue immunity from vaccine trials. Sci Transl Med 2023; 15:eadh3067. [PMID: 37437017 DOI: 10.1126/scitranslmed.adh3067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Accepted: 06/08/2023] [Indexed: 07/14/2023]
Abstract
The quest for an effective dengue vaccine has culminated in two approved vaccines and another that has completed phase 3 clinical trials. However, shortcomings exist in each, suggesting that the knowledge on dengue immunity used to develop these vaccines was incomplete. Vaccine trial findings could refine our understanding of dengue immunity, because these are experimentally derived, placebo-controlled data. Results from these trials suggest that neutralizing antibody titers alone are insufficient to inform protection against symptomatic infection, implicating a role for cellular immunity in protection. These findings have relevance for both future dengue vaccine development and application of current vaccines for maximal public health benefit.
Collapse
Affiliation(s)
- Eng Eong Ooi
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
- Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore 169857, Singapore
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore 117549, Singapore
| | - Shirin Kalimuddin
- Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore
- Department of Infectious Diseases, Singapore General Hospital, Singapore 169856, Singapore
| |
Collapse
|
3
|
Lin L, Koren MA, Paolino KM, Eckels KH, De La Barrera R, Friberg H, Currier JR, Gromowski GD, Aronson NE, Keiser PB, Sklar MJ, Sondergaard EL, Jasper LE, Endy TP, Jarman RG, Thomas SJ. Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial. J Infect Dis 2020; 223:1707-1716. [PMID: 32966573 DOI: 10.1093/infdis/jiaa603] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2020] [Accepted: 09/18/2020] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Dengue is a global health problem and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime-boost strategy has the advantage of eliciting immune responses through different mechanisms and therefore may be superior to homologous prime-boost strategies for generating durable tetravalent immunity. METHODS In this phase 1 first-in-human heterologous prime-boost study, 80 volunteers were assigned to 4 groups and received a tetravalent dengue virus (DENV-1-4) purified inactivated vaccine (TDENV-PIV) with alum adjuvant and a tetravalent dengue virus (DENV-1-4) live attenuated vaccine (TDENV-LAV) in different orders and dosing schedules (28 or 180 days apart). RESULTS All vaccination regimens had acceptable safety profiles and there were no vaccine-related serious adverse events. TDEN-PIV followed by TDEN-LAV induced higher neutralizing antibody titers and a higher rate of tetravalent seroconversions compared to TDEN-LAV followed by TDEN-PIV. Both TDEN-PIV followed by TDEN-LAV groups demonstrated 100% tetravalent seroconversion 28 days following the booster dose, which was maintained for most of these subjects through the day 180 measurement. CONCLUSIONS A heterologous prime-boost vaccination strategy for dengue merits additional evaluation for safety, immunogenicity, and potential for clinical benefit. CLINICAL TRIALS REGISTRATION NCT02239614.
Collapse
Affiliation(s)
- Leyi Lin
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Michael A Koren
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Kristopher M Paolino
- Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Kenneth H Eckels
- Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Rafael De La Barrera
- Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Heather Friberg
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Jeffrey R Currier
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Gregory D Gromowski
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Naomi E Aronson
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
| | - Paul B Keiser
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Marvin J Sklar
- Naval Medical Research Center, Silver Spring, Maryland, USA
| | - Erica L Sondergaard
- Clinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Louis E Jasper
- US Army Medical Materiel Development Activity, Frederick, Maryland, USA
| | - Timothy P Endy
- SUNY Upstate Medical University, Institute for Global Health and Translational Sciences, Syracuse, New York, USA
| | - Richard G Jarman
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| | - Stephen J Thomas
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
| |
Collapse
|
4
|
Verma M, Bhatnagar S, Kumari K, Mittal N, Sukhralia S, Gopirajan At S, Dhanaraj PS, Lal R. Highly conserved epitopes of DENV structural and non-structural proteins: Candidates for universal vaccine targets. Gene 2019; 695:18-25. [PMID: 30738967 PMCID: PMC7125761 DOI: 10.1016/j.gene.2019.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 01/22/2019] [Accepted: 02/01/2019] [Indexed: 12/11/2022]
Abstract
Dengue is a severe emerging arthropod borne viral disease occurring globally. Around two fifths of the world's population, or up to 3.9 billion people, are at a risk of dengue infection. Infection induces a life-long protective immunity to the homologous serotype but confers only partial and transient protection against subsequent infection caused by other serotypes. Thus, there is a need for a vaccine which is capable of providing a life- long protection against all the serotypes of dengue virus. In our study, comparative genomics of Dengue virus (DENV) was conducted to explore potential candidates for novel vaccine targets. From our analysis we successfully found 100% conserved epitopes in Envelope protein (RCPTQGE); NS3 (SAAQRRGR, PGTSGSPI); NS4A (QRTPQDNQL); NS4B (LQAKATREAQKRA) and NS5 proteins (QRGSGQV) in all DENV serotypes. Some serotype specific conserved motifs were also found in NS1, NS5, Capsid, PrM and Envelope proteins. Using comparative genomics and immunoinformatics approach, we could find conserved epitopes which can be explored as peptide vaccine candidates to combat dengue worldwide. Serotype specific epitopes can also be exploited for rapid diagnostics. All ten proteins are explored to find the conserved epitopes in DENV serotypes, thus making it the most extensively studied viral genome so far.
Collapse
Affiliation(s)
- Mansi Verma
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India; Molecular Biology Laboratory, Department of Zoology, University of Delhi, Delhi 110007, India.
| | - Shradha Bhatnagar
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - Kavita Kumari
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - Nidhi Mittal
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - Shivani Sukhralia
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - Shruthi Gopirajan At
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - P S Dhanaraj
- Sri Venkateswara College, South Campus, University of Delhi, New Delhi 110021, India
| | - Rup Lal
- Molecular Biology Laboratory, Department of Zoology, University of Delhi, Delhi 110007, India
| |
Collapse
|
5
|
Shukla R, Rajpoot RK, Arora U, Poddar A, Swaminathan S, Khanna N. Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo. Front Microbiol 2018; 8:2644. [PMID: 29367852 PMCID: PMC5768101 DOI: 10.3389/fmicb.2017.02644] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 12/19/2017] [Indexed: 12/02/2022] Open
Abstract
Dengue, a significant public health problem in several countries around the world, is caused by four different serotypes of mosquito-borne dengue viruses (DENV-1, -2, -3, and -4). Antibodies to any one DENV serotype which can protect against homotypic re-infection, do not offer heterotypic cross-protection. In fact, cross-reactive antibodies may augment heterotypic DENV infection through antibody-dependent enhancement (ADE). A recently launched live attenuated vaccine (LAV) for dengue, which consists of a mixture of four chimeric yellow-fever/dengue vaccine viruses, may be linked to the induction of disease-enhancing antibodies. This is likely related to viral interference among the replicating viral strains, resulting in an unbalanced immune response, as well as to the fact that the LAV encodes prM, a DENV protein documented to elicit ADE-mediating antibodies. This makes it imperative to explore the feasibility of alternate ADE risk-free vaccine candidates. Our quest for a non-replicating vaccine centered on the DENV envelope (E) protein which mediates virus entry into the host cell and serves as an important target of the immune response. Serotype-specific neutralizing epitopes and the host receptor recognition function map to E domain III (EDIII). Recently, we found that Pichia pastoris-expressed DENV E protein, of all four serotypes, self-assembled into virus-like particles (VLPs) in the absence of prM. Significantly, these VLPs displayed EDIII and elicited EDIII-focused DENV-neutralizing antibodies in mice. We now report the creation and characterization of a novel non-replicating recombinant particulate vaccine candidate, produced by co-expressing the E proteins of DENV-1 and DENV-2 in P. pastoris. The two E proteins co-assembled into bivalent mosaic VLPs (mVLPs) designated as mE1E2bv VLPs. The mVLP, which preserved the serotype-specific antigenic integrity of its two component proteins, elicited predominantly EDIII-focused homotypic virus-neutralizing antibodies in BALB/c mice, demonstrating its efficacy. In an in vivo ADE model, mE1E2bv VLP-induced antibodies lacked discernible ADE potential, compared to the cross-reactive monoclonal antibody 4G2, as evidenced by significant reduction in the levels of IL-6 and TNF-α, suggesting inherent safety. The results obtained with these bivalent mVLPs suggest the feasibility of incorporating the E proteins of DENV-3 and DENV-4 to create a tetravalent mVLP vaccine.
Collapse
Affiliation(s)
- Rahul Shukla
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Ravi K Rajpoot
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Upasana Arora
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Ankur Poddar
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Sathyamangalam Swaminathan
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Navin Khanna
- Recombinant Gene Products Group, Molecular Medicine Division, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.,Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, India.,Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States
| |
Collapse
|
6
|
Marcondes CB, Contigiani M, Gleiser RM. Emergent and Reemergent Arboviruses in South America and the Caribbean: Why So Many and Why Now? JOURNAL OF MEDICAL ENTOMOLOGY 2017; 54:509-532. [PMID: 28399216 DOI: 10.1093/jme/tjw209] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/07/2016] [Accepted: 10/20/2016] [Indexed: 06/07/2023]
Abstract
Varios arbovirus han emergido y/o reemergido en el Nuevo Mundo en las últimas décadas. Los virus Zika y chikungunya, anteriormente restringidos a África y quizás Asia, invadieron el continente, causando gran preocupación; además siguen ocurriendo brotes causados por el virus dengue en casi todos los países, con millones de casos por año. El virus West Nile invadió rápidamente América del Norte, y ya se han encontrado casos en América Central y del Sur. Otros arbovirus, como Mayaro y el virus de la encefalitis equina del este han aumentado su actividad y se han encontrado en nuevas regiones. Se han documentado cambios en la patogenicidad de algunos virus que conducen a enfermedades inesperadas. Una fauna diversa de mosquitos, cambios climáticos y en la vegetación, aumento de los viajes, y urbanizaciones no planificadas que generan condiciones adecuadas para la proliferación de Aedes aegypti (L.), Culex quinquefasciatus Say y otros mosquitos vectores, se han combinado para influir fuertemente en los cambios en la distribución y la incidencia de varios arbovirus. Se enfatiza la necesidad de realizar estudios exhaustivos de la fauna de mosquitos y modificaciones de las condiciones ambientales, sobre todo en las zonas urbanas fuertemente influenciadas por factores sociales, políticos y económicos.
Collapse
Affiliation(s)
- Carlos Brisola Marcondes
- Departamento de Microbiologia, Imunologia e Parasitologia, Centro de Ciências Biológicas, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina 88040-900, Brazil
| | - Marta Contigiani
- Emeritus Professor, Instituto de Virologia "Dr. J. M. Vanella", Enfermera Gordillo Gomez s/n, Ciudad Universitaria, National University of Córdoba, Córdoba, Argentina
| | - Raquel Miranda Gleiser
- Centro de Relevamiento y Evaluación de Recursos Agrícolas y Naturales (CREAN) - Instituto Multidisciplinario de Biología Vegetal (IMBIV), Universidad Nacional de Córdoba (UNC) and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Córdoba, Argentina
| |
Collapse
|
7
|
Khetarpal N, Shukla R, Rajpoot RK, Poddar A, Pal M, Swaminathan S, Arora U, Khanna N. Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. Am J Trop Med Hyg 2016; 96:126-134. [PMID: 27821688 DOI: 10.4269/ajtmh.16-0503] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2016] [Accepted: 09/27/2016] [Indexed: 12/11/2022] Open
Abstract
Dengue is a viral pandemic caused by four dengue virus serotypes (DENV-1, 2, 3, and 4) transmitted by Aedes mosquitoes. Reportedly, there has been a 2-fold increase in dengue cases every decade. An efficacious tetravalent vaccine, which can provide long-term immunity against all four serotypes in all target populations, is still unavailable. Despite the progress being made in the live virus-based dengue vaccines, the World Health Organization strongly recommends the development of alternative approaches for safe, affordable, and efficacious dengue vaccine candidates. We have explored virus-like particles (VLPs)-based nonreplicating subunit vaccine approach and have developed recombinant envelope ectodomains of DENV-1, 2, and 3 expressed in Pichia pastoris These self-assembled into VLPs without pre-membrane (prM) protein, which limits the generation of enhancing antibodies, and elicited type-specific neutralizing antibodies against the respective serotype. Encouraged by these results, we have extended this work further by developing P. pastoris-expressed DENV-4 ectodomain (DENV-4 E) in this study, which was found to be glycosylated and assembled into spherical VLPs without prM, and displayed critical neutralizing epitopes on its surface. These VLPs were found to be immunogenic in mice and elicited DENV-4-specific neutralizing antibodies, which were predominantly directed against envelope domain III, implicated in host-receptor recognition and virus entry. These observations underscore the potential of VLP-based nonreplicative vaccine approach as a means to develop a safe, efficacious, and tetravalent dengue subunit vaccine. This work paves the way for the evaluation of a DENV E-based tetravalent dengue vaccine candidate, as an alternative to live virus-based dengue vaccines.
Collapse
Affiliation(s)
- Niyati Khetarpal
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Rahul Shukla
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Ravi Kant Rajpoot
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Ankur Poddar
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Meena Pal
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | | | - Upasana Arora
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
| | - Navin Khanna
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| |
Collapse
|
8
|
Poddar A, Ramasamy V, Shukla R, Rajpoot RK, Arora U, Jain SK, Swaminathan S, Khanna N. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies. BMC Biotechnol 2016; 16:50. [PMID: 27301568 PMCID: PMC4908714 DOI: 10.1186/s12896-016-0280-y] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Accepted: 06/08/2016] [Indexed: 11/29/2022] Open
Abstract
Background Four antigenically distinct serotypes (1–4) of dengue viruses (DENVs) cause dengue disease. Antibodies to any one DENV serotype have the potential to predispose an individual to more severe disease upon infection with a different DENV serotype. A dengue vaccine must elicit homotypic neutralizing antibodies to all four DENV serotypes to avoid the risk of such antibody-dependent enhancement in the vaccine recipient. This is a formidable challenge as evident from the lack of protective efficacy against DENV-2 by a tetravalent live attenuated dengue vaccine that has completed phase III trials recently. These trial data underscore the need to explore non-replicating subunit vaccine alternatives. Recently, using the methylotrophic yeast Pichia pastoris, we showed that DENV-2 and DENV-3 envelope (E) glycoproteins, expressed in absence of prM, implicated in causing severe dengue disease, self-assemble into virus-like particles (VLPs), which elicit predominantly virus-neutralizing antibodies and confer significant protection against lethal DENV challenge in an animal model. The current study extends this work to a third DENV serotype. Results We cloned and expressed DENV-1 E antigen in P. pastoris, and purified it to near homogeneity. Recombinant DENV-1 E underwent post-translational processing, namely, signal peptide cleavage and glycosylation. Purified DENV-1 E self-assembled into stable VLPs, based on electron microscopy and dynamic light scattering analysis. Epitope mapping with monoclonal antibodies revealed that the VLPs retained the overall antigenic integrity of the virion particles despite the absence of prM. Subtle changes accompanied the efficient display of E domain III (EDIII), which contains type-specific neutralizing epitopes. These VLPs were immunogenic, eliciting predominantly homotypic EDIII-directed DENV-1-specific neutralizing antibodies. Conclusions This work demonstrates the inherent potential of P. pastoris-expressed DENV-1 E glycoprotein to self-assemble into VLPs eliciting predominantly homotypic neutralizing antibodies. This work justifies an investigation of the last remaining serotype, namely, DENV-4, to assess if it also shares the desirable vaccine potential manifested by the remaining three DENV serotypes. Such efforts could make it possible to envisage the development of a tetravalent dengue vaccine based on VLPs of P. pastoris-expressed E glycoproteins of the four DENV serotypes. Electronic supplementary material The online version of this article (doi:10.1186/s12896-016-0280-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ankur Poddar
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
| | - Viswanathan Ramasamy
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India.,Department of Biotechnology, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India
| | - Rahul Shukla
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India
| | - Ravi Kant Rajpoot
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India
| | - Upasana Arora
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India
| | - Swatantra K Jain
- Department of Biotechnology, Jamia Hamdard, Hamdard Nagar, New Delhi, 110062, India.,Department of Biochemistry, HIMSR, Jamia Hamdard, New Delhi, 110062, India
| | - Sathyamangalam Swaminathan
- Department of Biological Sciences, Birla Institute of Technology & Science, Jawahar Nagar, Shamirpet, Hyderabad, 500078, India.
| | - Navin Khanna
- Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India.
| |
Collapse
|
9
|
Simmons M, Sun P, Putnak R. Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine. PLoS One 2016; 11:e0152811. [PMID: 27035715 PMCID: PMC4818016 DOI: 10.1371/journal.pone.0152811] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Accepted: 03/19/2016] [Indexed: 12/04/2022] Open
Abstract
Dengue virus purified inactivated vaccines (PIV) are highly immunogenic and protective over the short term, but may be poor at inducing cell-mediated immune responses and long-term protection. The dengue nonstructural protein 3 (NS3) is considered the main target for T-cell responses during viral infection. The amino (N)-terminal protease and the carboxy (C)-terminal helicase domains of DENV-2 NS3 were expressed in E. coli and analyzed for their immune-potentiating capacity. Mice were immunized with DENV-2 PIV with and without recombinant NS3 protease or NS3 helicase proteins, and NS3 proteins alone on days 0, 14 and 28. The NS3 helicase but not the NS3 protease was effective in inducing T-cell responses quantified by IFN-γ ELISPOT. In addition, markedly increased total IgG antibody titer against virus antigen was seen in mice immunized with the PIV/NS3 helicase combination in the ELISA, as well as increased neutralizing antibody titer measured by the plaque reduction neutralization test. These results indicate the potential immunogenic properties of the NS3 helicase protein and its use in a dengue vaccine formulation.
Collapse
Affiliation(s)
- Monika Simmons
- Viral and Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, United States of America
| | - Peifang Sun
- Viral and Rickettsial Diseases Department, Naval Medical Research Center, Silver Spring, Maryland, United States of America
| | - Robert Putnak
- Division of Viral Diseases, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America
| |
Collapse
|
10
|
Cross-protection induced by Japanese encephalitis vaccines against different genotypes of Dengue viruses in mice. Sci Rep 2016; 6:19953. [PMID: 26818736 PMCID: PMC4730143 DOI: 10.1038/srep19953] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 12/21/2015] [Indexed: 01/13/2023] Open
Abstract
Dengue viruses (DENVs) and Japanese encephalitis virus (JEV) are closely related mosquito-borne flaviviruses that cause very high global disease burdens. Although cross-reactivity and cross-protection within flaviviruses have been demonstrated, the effect of JEV vaccination on susceptibility to DENV infection has not been well elucidated. In this study, we found that vaccination with the JEV inactivated vaccine (INV) and live attenuated vaccine (LAV) could induce cross-immune responses and cross-protection against DENV1-4 in mice. Despite the theoretical risk of immune enhancement, no increased mortality was observed in our mouse model. Additionally, low but consistently detectable cross-neutralizing antibodies against DENV2 and DENV3 were also observed in the sera of JEV vaccine-immunized human donors. The results suggested that both JEV-LAV and JEV-INV could elicit strong cross-immunity and protection against DENVs, indicating that inoculation with JEV vaccines may influence the distribution of DENVs in co-circulated areas and that the cross-protection induced by JEV vaccines against DENVs might provide important information in terms of DENV prevention.
Collapse
|
11
|
Abstract
Dengue is one of the most important vector-borne disease and an increasing problem worldwide because of current globalization trends. Roughly, half the world's population lives in dengue endemic countries, and nearly 100 million people are infected annually with dengue. India has the highest burden of the disease with 34% of the global cases. In the context of an expanding and potentially fatal infectious disease without effective prevention or specific treatment, the public health value of a protective vaccine is clear. There is no licensed dengue vaccine is available still, but several vaccines are under development. Keeping in view the rise in dengue prevalence globally, there is a need to increase clinical drug and vaccine research on dengue. This paper briefly reviews on the development and current status of dengue vaccine to provide information to policymakers, researchers, and public health experts to design and implement appropriate vaccine for prophylactic intervention.
Collapse
Affiliation(s)
- Priya Marimuthu
- Department of Pharmacology, SRM Medical College, Kattankulathur, Kanchipuram, Tamil Nadu, India
| | - Jamuna Rani Ravinder
- Department of Pharmacology, SRM Medical College, Kattankulathur, Kanchipuram, Tamil Nadu, India
| |
Collapse
|
12
|
Tripathi L, Mani S, Raut R, Poddar A, Tyagi P, Arora U, de Silva A, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Front Microbiol 2015; 6:1005. [PMID: 26441930 PMCID: PMC4585145 DOI: 10.3389/fmicb.2015.01005] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 09/07/2015] [Indexed: 11/28/2022] Open
Abstract
Dengue poses a serious public health risk to nearly half the global population. It causes ~400 million infections annually and is considered to be one of the fastest spreading vector-borne diseases. Four distinct serotypes of dengue viruses (DENV-1, -2, -3, and -4) cause dengue disease, which may be either mild or extremely severe. Antibody-dependent enhancement (ADE), by pre-existing cross-reactive antibodies, is considered to be the major mechanism underlying severe disease. This mandates that a preventive vaccine must confer simultaneous and durable immunity to each of the four prevalent DENV serotypes. Recently, we used Pichia pastoris, to express recombinant DENV-2 E ectodomain, and found that it assembled into virus-like particles (VLPs), in the absence of prM, implicated in the elicitation of ADE-mediating antibodies. These VLPs elicited predominantly type-specific neutralizing antibodies that conferred significant protection against lethal DENV-2 challenge, in a mouse model. The current work is an extension of this approach to develop prM-lacking DENV-3 E VLPs. Our data reveal that P. pastoris-produced DENV-3 E VLPs not only preserve the antigenic integrity of the major neutralizing epitopes, but also elicit potent DENV-3 virus-neutralizing antibodies. Further, these neutralizing antibodies appear to be exclusively directed toward domain III of the DENV-3 E VLPs. Significantly, they also lack discernible ADE potential toward heterotypic DENVs. Taken together with the high productivity of the P. pastoris expression system, this approach could potentially pave the way toward developing a DENV E-based, inexpensive, safe, and efficacious tetravalent sub-unit vaccine, for use in resource-poor dengue endemic countries.
Collapse
Affiliation(s)
- Lav Tripathi
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Shailendra Mani
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Rajendra Raut
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Ankur Poddar
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Poornima Tyagi
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Upasana Arora
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India
| | - Aravinda de Silva
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC USA
| | | | - Navin Khanna
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi India ; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad India ; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA USA
| |
Collapse
|
13
|
Huang TH, Tien NY, Luo YP. An in vitro bioassay for the quantitative evaluation of mosquito repellents against Stegomyia aegypti (=Aedes aegypti) mosquitoes using a novel cocktail meal. MEDICAL AND VETERINARY ENTOMOLOGY 2015; 29:238-244. [PMID: 25828787 DOI: 10.1111/mve.12114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/24/2014] [Revised: 12/11/2014] [Accepted: 01/20/2015] [Indexed: 06/04/2023]
Abstract
To assess the efficacy of new insect repellents, an efficient and safe in vitro bioassay system using a multiple-membrane blood-feeding device and a cocktail meal was developed. The multiple-membrane blood-feeding device facilitates the identification of new insect repellents by the high-throughput screening of candidate chemicals. A cocktail meal was developed as a replacement for blood for feeding females of Stegomyia aegypti (=Aedes aegypti) (L.) (Diptera: Culicidae). The cocktail meal consisted of a mixture of salt, albumin and dextrose, to which adenosine triphosphate was added to induce engorging. Feeding rates of St. aegypti on the cocktail meal and pig blood, respectively, did not differ significantly, but were significantly higher than the feeding rate on citrate phosphate dextrose-adenine 1 (CPDA-1) solutions, which had been used to replace bloodmeals in previous repellent assays. Dose-dependent biting inhibition rates were analysed using probit analysis. The RD(50) (the dose producing 50% repellence of mosquito feeding) values of DEET, citronella, carvacrol, geraniol, eugenol and thymol were 1.62, 14.40, 22.51, 23.29, 23.83 and 68.05 µg/cm(2), respectively.
Collapse
Affiliation(s)
- T-H Huang
- Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan
| | - N-Y Tien
- Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan
| | - Y-P Luo
- Department of Biotechnology, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan
| |
Collapse
|
14
|
Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ. Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial. Am J Trop Med Hyg 2015; 93:454-460. [PMID: 26149862 PMCID: PMC4559679 DOI: 10.4269/ajtmh.14-0819] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Accepted: 05/12/2015] [Indexed: 12/30/2022] Open
Abstract
We describe the results from a human clinical trial of a dengue virus serotype-1, purified-inactivated vaccine (DENV-1 PIV) adjuvanted with aluminum hydroxide. This first-in-man, Phase 1, open-label clinical trial consisted of two groups of flavivirus-naïve healthy adult volunteers that received two intramuscular vaccine doses of either 2.5 μg or 5 μg of DENV-1 PIV administered on days 0 and 28. Following vaccination, both vaccine doses exhibited an acceptable safety profile with minimal injection site and systemic reactions. By study day 42, 2 weeks following the second vaccine dose, all volunteers in both vaccine groups developed serum-neutralizing antibodies against DENV-1. Additional testing using an enzyme-linked immunosorbent assay demonstrated induction of a humoral immune response following both vaccine doses. The DENV-1 PIV was safe and immunogenic in a small number of volunteers supporting development and further testing of a tetravalent DENV PIV formulation.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - Kenneth H. Eckels
- *Address correspondence to Kenneth H. Eckels, Translational Medicine Branch, Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910. E-mail:
| | | |
Collapse
|
15
|
Thomas SJ, Aldstadt J, Jarman RG, Buddhari D, Yoon IK, Richardson JH, Ponlawat A, Iamsirithaworn S, Scott TW, Rothman AL, Gibbons RV, Lambrechts L, Endy TP. Improving dengue virus capture rates in humans and vectors in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance strategy. Am J Trop Med Hyg 2015; 93:24-32. [PMID: 25986580 DOI: 10.4269/ajtmh.14-0242] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Accepted: 01/02/2015] [Indexed: 11/07/2022] Open
Abstract
Dengue is of public health importance in tropical and sub-tropical regions. Dengue virus (DENV) transmission dynamics was studied in Kamphaeng Phet Province, Thailand, using an enhanced spatiotemporal surveillance of 93 hospitalized subjects with confirmed dengue (initiates) and associated cluster individuals (associates) with entomologic sampling. A total of 438 associates were enrolled from 208 houses with household members with a history of fever, located within a 200-m radius of an initiate case. Of 409 associates, 86 (21%) had laboratory-confirmed DENV infection. A total of 63 (1.8%) of the 3,565 mosquitoes collected were dengue polymerase chain reaction positive (PCR+). There was a significant relationship between spatial proximity to the initiate case and likelihood of detecting DENV from associate cases and Aedes mosquitoes. The viral detection rate from human hosts and mosquito vectors in this study was higher than previously observed by the study team in the same geographic area using different methodologies. We propose that the sampling strategy used in this study could support surveillance of DENV transmission and vector interactions.
Collapse
Affiliation(s)
- Stephen J Thomas
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Jared Aldstadt
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Richard G Jarman
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Darunee Buddhari
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - In-Kyu Yoon
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Jason H Richardson
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Alongkot Ponlawat
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Sopon Iamsirithaworn
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Thomas W Scott
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Alan L Rothman
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Robert V Gibbons
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Louis Lambrechts
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| | - Timothy P Endy
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Department of Virology, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Department of Geography, University at Buffalo, Buffalo, New York; Department of Entomology, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand; Bureau of Epidemiology, Department of Disease Control Sciences, Ministry of Public Health, Nonthaburi, Thailand; Department of Entomology, University of California, Davis, Davis, California; Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhode Island; Insect-Virus Interactions Group, Department of Genomes and Genetics, Institut Pasteur, Centre National de la Recherche Scientifique, Paris, France; Department of Infectious Diseases, State University of New York, Syracuse, New York; Fogarty International Center, National Institutes of Health, Bethesda, Maryland
| |
Collapse
|
16
|
Ghosh A, Dar L. Dengue vaccines: Challenges, development, current status and prospects. Indian J Med Microbiol 2015; 33:3-15. [DOI: 10.4103/0255-0857.148369] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
|
17
|
Wei J, Chen H, An J. Recent progress in dengue vaccine development. Virol Sin 2014; 29:353-63. [PMID: 25547681 PMCID: PMC8206420 DOI: 10.1007/s12250-014-3542-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2014] [Accepted: 12/16/2014] [Indexed: 10/24/2022] Open
Abstract
Dengue virus (DENV) has four distinct serotypes. DENV infection can result in classic dengue fever and life-threatening dengue hemorrhagic fever/dengue shock syndrome. In recent decades, DENV infection has become an important public health concern in epidemic-prone areas. Vaccination is the most effective measure to prevent and control viral infections. However, several challenges impede the development of effective DENV vaccines, such as the lack of suitable animal models and the antibody-dependent enhancement phenomenon. Although no licensed DENV vaccine is available, significant progress has been made. This review summarizes candidate DENV vaccines from recent investigations.
Collapse
Affiliation(s)
- Jianchun Wei
- Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069 China
| | - Hui Chen
- Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069 China
| | - Jing An
- Department of Microbiology, School of Basic Medical Sciences, Capital Medical University, Beijing, 100069 China
| |
Collapse
|
18
|
Advances in the understanding, management, and prevention of dengue. J Clin Virol 2014; 64:153-9. [PMID: 25453329 DOI: 10.1016/j.jcv.2014.08.031] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2014] [Accepted: 08/25/2014] [Indexed: 01/09/2023]
Abstract
Dengue causes more human morbidity globally than any other vector-borne viral disease. Recent research has led to improved epidemiological methods that predict disease burden and factors involved in transmission, a better understanding of immune responses in infection, and enhanced animal models. In addition, a number of control measures, including preventative vaccines, are in clinical trials. However, significant gaps remain, including the need for better surveillance in large parts of the world, methods to predict which individuals will develop severe disease, and immunologic correlates of protection against dengue illness. During the next decade, dengue will likely expand its geographic reach and become an increasing burden on health resources in affected areas. Licensed vaccines and antiviral agents are needed in order to effectively control dengue and limit disease.
Collapse
|
19
|
Mackey TK, Liang BA, Cuomo R, Hafen R, Brouwer KC, Lee DE. Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment. Clin Microbiol Rev 2014; 27:949-79. [PMID: 25278579 PMCID: PMC4187634 DOI: 10.1128/cmr.00045-14] [Citation(s) in RCA: 116] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
In global health, critical challenges have arisen from infectious diseases, including the emergence and reemergence of old and new infectious diseases. Emergence and reemergence are accelerated by rapid human development, including numerous changes in demographics, populations, and the environment. This has also led to zoonoses in the changing human-animal ecosystem, which are impacted by a growing globalized society where pathogens do not recognize geopolitical borders. Within this context, neglected tropical infectious diseases have historically lacked adequate attention in international public health efforts, leading to insufficient prevention and treatment options. This subset of 17 infectious tropical diseases disproportionately impacts the world's poorest, represents a significant and underappreciated global disease burden, and is a major barrier to development efforts to alleviate poverty and improve human health. Neglected tropical diseases that are also categorized as emerging or reemerging infectious diseases are an even more serious threat and have not been adequately examined or discussed in terms of their unique risk characteristics. This review sets out to identify emerging and reemerging neglected tropical diseases and explore the policy and innovation environment that could hamper or enable control efforts. Through this examination, we hope to raise awareness and guide potential approaches to addressing this global health concern.
Collapse
Affiliation(s)
- Tim K Mackey
- Department of Anesthesiology, University of California, San Diego, School of Medicine, San Diego, California, USA Division of Global Public Health, University of California, San Diego, Department of Medicine, San Diego, California, USA
| | - Bryan A Liang
- Department of Anesthesiology, University of California, San Diego, School of Medicine, San Diego, California, USA
| | - Raphael Cuomo
- Joint Doctoral Program in Global Public Health, University of California, San Diego, and San Diego State University, San Diego, California, USA
| | - Ryan Hafen
- Department of Anesthesiology, University of California, San Diego, School of Medicine, San Diego, California, USA Internal Medicine, University of California, San Diego, School of Medicine, San Diego, California, USA
| | - Kimberly C Brouwer
- Division of Global Public Health, University of California, San Diego, Department of Medicine, San Diego, California, USA
| | - Daniel E Lee
- Department of Anesthesiology, University of California, San Diego, School of Medicine, San Diego, California, USA Pediatrics Department, University of California, San Diego, School of Medicine, San Diego, California, USA
| |
Collapse
|
20
|
da Costa VG, Marques-Silva AC, Floriano VG, Moreli ML. Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials. Vaccine 2014; 32:4885-92. [DOI: 10.1016/j.vaccine.2014.07.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2014] [Revised: 06/17/2014] [Accepted: 07/08/2014] [Indexed: 12/30/2022]
|
21
|
Affiliation(s)
- M Cristina Cassetti
- Virology Branch, National Institute of Allergy and Infectious Diseases, Bethesda
| | - Stephen J Thomas
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland
| |
Collapse
|
22
|
Shepherd SM, Shoff WH. Vaccination for the expatriate and long-term traveler. Expert Rev Vaccines 2014; 13:775-800. [DOI: 10.1586/14760584.2014.913485] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
23
|
Thisyakorn U, Capeding MR, Goh DYT, Hadinegoro SR, Ismail Z, Tantawichien T, Yoksan S, Pang T. Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop. Expert Rev Vaccines 2014; 13:581-7. [DOI: 10.1586/14760584.2014.907529] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Usa Thisyakorn
- Department of Paediatrics, Faculty of Medicine, Chulalongkorn University,
Bangkok, Thailand
| | | | | | - Sri Rezeki Hadinegoro
- Department of Child Health, Faculty of Medicine, University of Indonesia,
Jakarta, Indonesia
| | | | | | - Sutee Yoksan
- Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University,
Bangkok, Thailand
| | - Tikki Pang
- Lee Kuan Yew School of Public Policy, National University of Singapore, Singapore
| |
Collapse
|
24
|
Lam SK. Challenges in reducing dengue burden; diagnostics, control measures and vaccines. Expert Rev Vaccines 2014; 12:995-1010. [PMID: 24053394 DOI: 10.1586/14760584.2013.824712] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Dengue is a major public health concern worldwide, with the number of infections increasing globally. The illness imposes the greatest economic and human burden on developing countries that have limited resources to deal with the scale of the problem. No cure for dengue exists; treatment is limited to rehydration therapy, and with vector control strategies proving to be relatively ineffective, a vaccine is an urgent priority. Despite the numerous challenges encountered in the development of a dengue vaccine, several vaccine candidates have shown promise in clinical development and it is believed that a vaccination program would be at least as cost-effective as current vector control programs. The lead candidate vaccine is a tetravalent, live attenuated, recombinant vaccine, which is currently in Phase III clinical trials. Vaccine introduction is a complex process that requires consideration and is discussed here. This review discusses the epidemiology, burden and pathogenesis of dengue, as well as the vaccine candidates currently in clinical development.
Collapse
Affiliation(s)
- Sai Kit Lam
- Office of the Vice-Chancellor, University of Malaya, Jalan Pantai Baru, 50603, Kuala Lumpur, Malaysia +60 17 8800044 +60 37 7259635
| |
Collapse
|
25
|
Jindal H, Bhatt B, Malik JS, SK S. Dengue vaccine: a valuable asset for the future. Hum Vaccin Immunother 2014; 10:2245-6. [PMID: 25424928 PMCID: PMC4896803 DOI: 10.4161/hv.28953] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 04/20/2014] [Indexed: 11/19/2022] Open
Abstract
Dengue has emerged as one of the major global public health problems. The disease has broken out of its shell and has spread due to increased international travel and climatic changes. Globally, over 2.5 billion people accounting for >40% of the world's population are at risk from dengue. Since the 1940s, dengue vaccines have been under investigation. A live-attenuated tetravalent vaccine based on chimeric yellow fever-dengue virus (CYD-TDV) has progressed to phase III efficacy studies. Dengue vaccine has been found to be a cost-effective intervention to reduce morbidity and mortality. Current dengue vaccine candidates aim to protect against the 4 dengue serotypes, but the recent discovery of a fifth serotype could complicate vaccine development. In recent years, an urgent need has been felt for a vaccine to prevent the morbidity and mortality from this disease in a cost-effective way.
Collapse
Affiliation(s)
| | - Bhumika Bhatt
- Department of Community Medicine; PGIMS; Rohtak, Haryana, India
| | | | - Shashikantha SK
- Department of Community Medicine; PGIMS; Rohtak, Haryana, India
| |
Collapse
|
26
|
Mani S, Tripathi L, Raut R, Tyagi P, Arora U, Barman T, Sood R, Galav A, Wahala W, de Silva A, Swaminathan S, Khanna N. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. PLoS One 2013; 8:e64595. [PMID: 23717637 PMCID: PMC3662778 DOI: 10.1371/journal.pone.0064595] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2013] [Accepted: 04/15/2013] [Indexed: 11/22/2022] Open
Abstract
Dengue is a mosquito-borne viral disease with a global prevalence. It is caused by four closely-related dengue viruses (DENVs 1–4). A dengue vaccine that can protect against all four viruses is an unmet public health need. Live attenuated vaccine development efforts have encountered unexpected interactions between the vaccine viruses, raising safety concerns. This has emphasized the need to explore non-replicating dengue vaccine options. Virus-like particles (VLPs) which can elicit robust immunity in the absence of infection offer potential promise for the development of non-replicating dengue vaccine alternatives. We have used the methylotrophic yeast Pichia pastoris to develop DENV envelope (E) protein-based VLPs. We designed a synthetic codon-optimized gene, encoding the N-terminal 395 amino acid residues of the DENV-2 E protein. It also included 5’ pre-membrane-derived signal peptide-encoding sequences to ensure proper translational processing, and 3’ 6× His tag-encoding sequences to facilitate purification of the expressed protein. This gene was integrated into the genome of P. pastoris host and expressed under the alcohol oxidase 1 promoter by methanol induction. Recombinant DENV-2 protein, which was present in the insoluble membrane fraction, was extracted and purified using Ni2+-affinity chromatography under denaturing conditions. Amino terminal sequencing and detection of glycosylation indicated that DENV-2 E had undergone proper post-translational processing. Electron microscopy revealed the presence of discrete VLPs in the purified protein preparation after dialysis. The E protein present in these VLPs was recognized by two different conformation-sensitive monoclonal antibodies. Low doses of DENV-2 E VLPs formulated in alum were immunogenic in inbred and outbred mice eliciting virus neutralizing titers >1∶1200 in flow cytometry based assays and protected AG129 mice against lethal challenge (p<0.05). The formation of immunogenic DENV-2 E VLPs in the absence of pre-membrane protein highlights the potential of P. pastoris in developing non-replicating, safe, efficacious and affordable dengue vaccine.
Collapse
Affiliation(s)
- Shailendra Mani
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Lav Tripathi
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Rajendra Raut
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Poornima Tyagi
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Upasana Arora
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Tarani Barman
- Department of Infectious Diseases, Ranbaxy Research Laboratories, Udyog Vihar, Gurgaon, Haryana, India
| | - Ruchi Sood
- Department of Infectious Diseases, Ranbaxy Research Laboratories, Udyog Vihar, Gurgaon, Haryana, India
| | - Alka Galav
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
| | - Wahala Wahala
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
| | - Aravinda de Silva
- Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America
| | - Sathyamangalam Swaminathan
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
- * E-mail: (SS); (NK)
| | - Navin Khanna
- Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India
- * E-mail: (SS); (NK)
| |
Collapse
|
27
|
Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013; 88:73-88. [PMID: 23208878 PMCID: PMC3541749 DOI: 10.4269/ajtmh.2012.12-0361] [Citation(s) in RCA: 75] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2012] [Accepted: 09/29/2012] [Indexed: 01/30/2023] Open
Abstract
Two formulations of a new live tetravalent dengue virus (DENV) vaccine produced using re-derived master seeds from a precursor vaccine and that same precursor vaccine as a control were compared in a placebo-controlled, randomized, observer-blind, phase II trial of 86 healthy adults. Two vaccine doses were administered 6 months apart; a third dose was offered to a subset. Symptoms and signs of dengue-like illness reported after vaccination were mild to moderate, transient, and occurred with similar frequency among recipients of the new DENV vaccine and placebo, except for rash. Neither dengue nor vaccine-related serious adverse events were reported. The first DENV vaccine dose was moderately immunogenic; the second dose increased the potency and breadth of the neutralizing antibody response. Tetravalent response rates to the new formulations were 60% and 66.7% in unprimed subjects. A third dose did not increase tetravalent antibody rates. The new DENV vaccine candidates merit additional evaluation.
Collapse
Affiliation(s)
- Stephen J. Thomas
- Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland; Division of Regulated Activities, Pilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, Maryland; GlaxoSmithKline Vaccines, Wavre, Belgium; United States Army Medical Component—Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand; GlaxoSmithKline Vaccines, King of Prussia, Pennsylvania
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol 2012; 3:334. [PMID: 23162552 PMCID: PMC3492872 DOI: 10.3389/fimmu.2012.00334] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Accepted: 10/20/2012] [Indexed: 11/13/2022] Open
Abstract
Dengue viruses (DENV) are the most important mosquito transmitted viral pathogens infecting humans. DENV infection produces a spectrum of disease, most commonly causing a self-limiting flu-like illness known as dengue fever; yet with increased frequency, manifesting as life-threatening dengue hemorrhagic fever (DHF). Waning cross-protective immunity from any of the four dengue serotypes may enhance subsequent infection with another heterologous serotype to increase the probability of DHF. Decades of effort to develop dengue vaccines are reaching the finishing line with multiple candidates in clinical trials. Nevertheless, concerns remain that imbalanced immunity, due to the prolonged prime-boost schedules currently used in clinical trials, could leave some vaccinees temporarily unprotected or with increased susceptibility to enhanced disease. Here we develop a DENV serotype 1 (DENV-1) DNA vaccine with the immunodominant cross-reactive B cell epitopes associated with immune enhancement removed. We compare wild-type (WT) with this cross-reactivity reduced (CRR) vaccine and demonstrate that both vaccines are equally protective against lethal homologous DENV-1 challenge. Under conditions mimicking natural exposure prior to acquiring protective immunity, WT vaccinated mice enhanced a normally sub-lethal heterologous DENV-2 infection resulting in DHF-like disease and 95% mortality in AG129 mice. However, CRR vaccinated mice exhibited redirected serotype-specific and protective immunity, and significantly reduced morbidity and mortality not differing from naїve mice. Thus, we demonstrate in an in vivo DENV disease model, that non-protective vaccine-induced immunity can prime vaccinees for enhanced DHF-like disease and that CRR DNA immunization significantly reduces this potential vaccine safety concern. The sculpting of immune memory by the modified vaccine and resulting redirection of humoral immunity provide insight into DENV vaccine-induced immune responses.
Collapse
Affiliation(s)
- Wayne D Crill
- Arboviral Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Service Fort Collins, CO, USA
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
The endemic area for dengue fever extends over 60 countries, and approximately 2.5 billion people are at risk of infection. The incidence of dengue has multiplied many times over the last five decades at an alarming rate. In the endemic areas, waves of infection occur in epidemics, with thousands of individuals affected, creating a huge burden on the limited resources of a country's health care system. While the illness passes off as a simple febrile episode in many, a few have a severe illness marked by hypovolemic shock and bleeding. Iatrogenic fluid overload in the management may further complicate the picture. In this severe form dengue can be fatal. Tackling the burden of dengue is impeded by several issues, including a lack of understanding about the exact pathophysiology of the infection, inability to successfully control the vector population, lack of specific therapy against the virus, and the technical difficulties in developing a vaccine. This review provides an overview on the epidemiology, natural history, management strategies, and future directions for research on dengue, including the potential for development of a vaccine.
Collapse
Affiliation(s)
- Senaka Rajapakse
- Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Sri Lanka
| | | | | |
Collapse
|
30
|
Affiliation(s)
- Suzanne Moore Shepherd
- Department of Emergency Medicine, PENN Travel Medicine, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
| | | |
Collapse
|
31
|
Bargeron Clark K, Hsiao HM, Noisakran S, Tsai JJ, Perng GC. Role of microparticles in dengue virus infection and its impact on medical intervention strategies. THE YALE JOURNAL OF BIOLOGY AND MEDICINE 2012; 85:3-18. [PMID: 22461739 PMCID: PMC3313537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Dengue virus (DV) is one of the most important vector-borne diseases in the world. It causes a disease that manifests as a spectrum of clinical symptoms, including dengue hemorrhagic fever. DV is proficient at diverting the immune system to facilitate transmission through its vector host, Aedes spp. mosquito. Similar to other vector-borne parasites, dengue may also require a second structural form, a virus of alternative morphology (VAM), to complete its life cycle. DV can replicate to high copy numbers in patient plasma, but no classical viral particles can be detected by ultra-structural microscopy analysis. A VAM appearing as a microparticle has been recapitulated with in vitro cell lines Meg01 and K562, close relatives to the cells harboring dengue virus in vivo. VAMs are likely to contribute to the high viremia levels observed in dengue patients. This review discusses the possible existence of a VAM in the DV life cycle.
Collapse
Affiliation(s)
- Kristina Bargeron Clark
- Department of Pathology and Laboratory Medicine, Emory
Vaccine Center, Emory University School of Medicine, Atlanta, Georgia
| | - Hui-Mien Hsiao
- Department of Pathology and Laboratory Medicine, Emory
Vaccine Center, Emory University School of Medicine, Atlanta, Georgia
| | - Sansanee Noisakran
- Department of Pathology and Laboratory Medicine, Emory
Vaccine Center, Emory University School of Medicine, Atlanta, Georgia
- Medical Biotechnology Unit, National Center for Genetic
Engineering and Biotechnology, National Science and Technology Development
Agency, Pathumthani 12120, Thailand
| | - Jih-Jin Tsai
- Tropical Medicine Center, Department of Internal
Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- Division of Infectious Diseases, Department of Internal
Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
- College of Medicine, Faculty of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan
| | - Guey Chuen Perng
- Department of Pathology and Laboratory Medicine, Emory
Vaccine Center, Emory University School of Medicine, Atlanta, Georgia
- Department of Microbiology and Immunology, National
Cheng Kung University Medical College, Tainan, Taiwan
- Center of Infectious Diseases and Signaling Research,
National Cheng Kung University Medical College, Tainan, Taiwan
| |
Collapse
|
32
|
|